Picard Medical (PMI) files 8-K on SynCardia Total Artificial Heart update

Rhea-AI Filing Summary

Picard Medical, Inc. filed a current report to note that it issued a press release on December 9, 2025 providing an update regarding its SynCardia Total Artificial Heart. The update itself is contained in the referenced press release, which is attached as Exhibit 99.1 and incorporated by reference.

The company clarifies that the information in this report and its exhibits is being furnished rather than filed, meaning it is not automatically subject to certain liability provisions or incorporated into other securities law filings. No financial results, transaction details, or changes in corporate structure are described in this report.

false 0002030617 0002030617 2025-12-09 2025-12-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 9, 2025

Picard Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-42801		86-3212894
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1992 E Silverlake
Tucson AZ, 85713

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (520) 545-1234

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		PMI		The NYSE American, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On December 9, 2025, Picard Medical, Inc. issued a press release announcing an update regarding the SynCardia Total Artificial Heart. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference herein.

The information in this report and the exhibits attached hereto shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed herewith:

Exhibit No.		Description
99.1		Picard Medical, Inc. Press Release dated December 9, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Picard Medical, Inc.
	By:	/s/ Patrick NJ Schnegelsberg
		Name:	Patrick NJ Schnegelsberg
		Title:	Chief Executive Officer

Dated: December 9, 2025

2

FAQ

What did Picard Medical, Inc. (PMI) announce in this 8-K?

Picard Medical, Inc. reported that it issued a press release on December 9, 2025 announcing an update regarding the SynCardia Total Artificial Heart. The details of the update are contained in Exhibit 99.1.

Which product is mentioned in Picard Medical, Inc.'s latest 8-K filing?

The filing refers to the SynCardia Total Artificial Heart, a key product for Picard Medical, Inc., and notes that a press release provides an update on this device.

Where can investors find the full details of Picard Medical, Inc.'s SynCardia Total Artificial Heart update?

The full details are included in the Picard Medical, Inc. press release dated December 9, 2025, which is attached to the report as Exhibit 99.1.

Does this Picard Medical, Inc. 8-K include new financial results?

No, the report does not present financial results. It primarily notes the issuance of a press release about an update related to the SynCardia Total Artificial Heart.

How is the information in this Picard Medical, Inc. 8-K treated under securities laws?

The company states that the information in the report and its exhibits is furnished, not filed, so it is not automatically subject to certain Exchange Act liabilities or incorporated into other Securities Act or Exchange Act filings.

Which exhibit in the 8-K contains Picard Medical, Inc.'s press release?

Exhibit 99.1 contains the Picard Medical, Inc. press release dated December 9, 2025 that provides the update regarding the SynCardia Total Artificial Heart.